[go: up one dir, main page]

NO20014657L - Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol - Google Patents

Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol

Info

Publication number
NO20014657L
NO20014657L NO20014657A NO20014657A NO20014657L NO 20014657 L NO20014657 L NO 20014657L NO 20014657 A NO20014657 A NO 20014657A NO 20014657 A NO20014657 A NO 20014657A NO 20014657 L NO20014657 L NO 20014657L
Authority
NO
Norway
Prior art keywords
cholesterol
density lipoprotein
verylow
vldl
apolipoprotein
Prior art date
Application number
NO20014657A
Other languages
Norwegian (no)
Other versions
NO20014657D0 (en
NO331779B1 (en
Inventor
Michael Jaye
Kevin J Lynch
Dilip V Amin
Kim-Anh Thi Doan
Dawn Marchadier
Cyrille Maugeais
Daniel J Rader
John A Krawiec
Victoria J South
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of NO20014657D0 publication Critical patent/NO20014657D0/en
Publication of NO20014657L publication Critical patent/NO20014657L/en
Publication of NO331779B1 publication Critical patent/NO331779B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20014657A 1999-03-26 2001-09-25 Methods for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein A1 or promote the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol or LDL cholesterol NO331779B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (3)

Publication Number Publication Date
NO20014657D0 NO20014657D0 (en) 2001-09-25
NO20014657L true NO20014657L (en) 2001-11-21
NO331779B1 NO331779B1 (en) 2012-03-26

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014657A NO331779B1 (en) 1999-03-26 2001-09-25 Methods for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein A1 or promote the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol or LDL cholesterol
NO20100214A NO331784B1 (en) 1999-03-26 2010-02-11 Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100214A NO331784B1 (en) 1999-03-26 2010-02-11 Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient.

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR20050044812A (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ531180A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
ES2600781T3 (en) 2008-12-04 2017-02-10 Curna, Inc. Treatment for diseases related to vascular endothelial growth factor (vegf) by inhibiting natural antisense transcripts of vegf
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
EP2370582B1 (en) 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CA2752237C (en) 2009-02-12 2020-03-24 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
ES2656290T3 (en) 2009-03-16 2018-02-26 Curna, Inc. Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
KR101835889B1 (en) 2009-05-06 2018-03-08 큐알엔에이, 인크. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
KR101742334B1 (en) 2009-05-08 2017-06-01 큐알엔에이, 인크. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
NO2432881T3 (en) 2009-05-18 2018-04-14
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2443237B1 (en) 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (en) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
JP2013500017A (en) 2009-07-24 2013-01-07 カッパーアールエヌエー，インコーポレイテッド Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8791087B2 (en) 2009-08-21 2014-07-29 Curna, Inc. Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6025567B2 (en) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
CN102781480B (en) 2009-12-23 2018-07-27 库尔纳公司 UCP2 relevant diseases are treated by inhibiting the natural antisense transcript of uncoupling protein-3 (UCP2)
KR101891352B1 (en) 2009-12-23 2018-08-24 큐알엔에이, 인크. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
WO2011082281A2 (en) 2009-12-31 2011-07-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CA2785832A1 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
JP5963680B2 (en) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
CN102803493B (en) 2010-01-11 2018-07-31 库尔纳公司 SHBG relevant diseases are treated by inhibiting the natural antisense transcript of sex hormone binding globulin (SHBG)
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
RU2608496C2 (en) 2010-02-22 2017-01-18 Курна, Инк. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP5978203B2 (en) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21
KR101992076B1 (en) 2010-05-03 2019-06-21 큐알엔에이, 인크. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
KR101902197B1 (en) 2010-05-26 2018-10-01 큐알엔에이, 인크. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
KR20180053419A (en) 2010-05-26 2018-05-21 큐알엔에이, 인크. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CA2803882C (en) 2010-06-23 2022-10-18 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2593547B1 (en) 2010-07-14 2017-11-15 CuRNA, Inc. Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
RU2624048C2 (en) 2010-10-06 2017-06-30 Курна, Инк. Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
RU2597972C2 (en) 2010-10-22 2016-09-20 Курна Инк. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
JP6071893B2 (en) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
EP2718439B1 (en) 2011-06-09 2017-08-09 CuRNA, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2753317B1 (en) 2011-09-06 2020-02-26 CuRNA, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
PT2825648T (en) 2012-03-15 2018-11-09 Scripps Research Inst Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
EP2915882B1 (en) * 2012-11-05 2018-10-17 Shionogi & Co., Ltd. Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
SG10201707233UA (en) 2013-03-14 2017-10-30 Shionogi & Co Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
TWI688575B (en) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
AP1313A (en) * 1996-12-06 2004-10-04 Aventis Pharma Inc Polypeptides encoded by a human lipase-like gene, composition and method.
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
NO331784B1 (en) 2012-03-26
WO2000057837A8 (en) 2001-09-27
NO20014657D0 (en) 2001-09-25
HK1043309A1 (en) 2002-09-13
KR20020029651A (en) 2002-04-19
EP1171078A2 (en) 2002-01-16
BR0009333A (en) 2002-01-08
WO2000057837A9 (en) 2001-10-18
NO20100214L (en) 2001-11-21
IL145526A0 (en) 2002-06-30
CA2363486A1 (en) 2000-10-05
NZ531180A (en) 2005-06-24
WO2000057837A2 (en) 2000-10-05
EP1171078A4 (en) 2002-11-06
NZ514350A (en) 2004-12-24
AU3918700A (en) 2000-10-16
KR100887164B1 (en) 2009-03-10
IL145526A (en) 2010-11-30
WO2000057837A3 (en) 2001-01-25
ZA200107598B (en) 2003-05-28
NO331779B1 (en) 2012-03-26
JP2002540127A (en) 2002-11-26
AU776684B2 (en) 2004-09-16
MXPA01009727A (en) 2002-07-22
KR20050044812A (en) 2005-05-12
CA2363486C (en) 2012-12-18

Similar Documents

Publication Publication Date Title
NO20014657D0 (en) Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol
NO984524D0 (en) Amphipathic molecules such as cholesterol and other lipid uptake inhibitors
IL147022A0 (en) Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
AU2002212717A1 (en) Test piece for assaying high density lipoprotein (hdl) cholesterol
AU2001241000A1 (en) System and method for computer searching
AU2001275539A1 (en) Method for authenticating and securing integrated bookstore entries
AU2001266578A1 (en) System and method for providing access to forms and maintaining the data used tocomplete the forms
NO20014029D0 (en) Organic sol and solid compound based on cerium oxide and an amphiphilic compound and process for preparation
NO20020779D0 (en) Methods, preparations and kits to promote healing of central nervous system damage
EP1212065A4 (en) Compositions and methods for raising hdl cholesterol levels
AU3239800A (en) Method and apparatus for improving access to literature
NO20004104D0 (en) Preparations comprising viruses and methods for concentrating virus preparations
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
AU4880801A (en) System and method for supporting businesses
IL155484A0 (en) Method and system for dynamically maintaining internet associations
AU2001251563A1 (en) Method and system for managing credentials
TWI319009B (en) Pretreatment method of samples for cholesterol quantitation, and quantitation method of cholesterol in specific lipoprotein by the use of the pretreatme
DE69931279D1 (en) METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA
AU1960600A (en) Method and apparatus for minimizing differential power attacks on processors
NO20005433D0 (en) Human BMP-7 promoter and method to explore bone related substance using the same
EP1059579A3 (en) Information processor and method for switching register files
AU6595700A (en) Method and apparatus for operating virtual computer
AU8023900A (en) System and methods for accessing internet information using internet appliances
AU7589498A (en) Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates
AU2001242846A1 (en) System and method operating as an agency for enabling registration and login

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees